Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,352.00up ₹7.00 (0.52%)BSE ₹1,350.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,345.00.
30 Oct: open ₹1,345.00, high ₹1,363.70, low ₹1,345.00
52-week range of traded prices to 30 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,849 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.30
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.91
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.59%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,14,05957.9% delivered
Dr. Reddy's Laboratories share news and announcements
1,702 announcements, routine notices left out, newest first. Page 34 of 35.
Feb 2008
8 Feb · Business
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding a press release dated February 08, 2008, titled "Dr. Reddy's Announces collaboration with SkyePharma for New Product utilizing two of SkyePharma's proprietary drug delivery systems". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2008
25 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated January 25, 2008, titled "Dr. Reddy's Q3 FY08 Revenue at Rs 12,320 million; EBITDA at Rs 2,037 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that "The Board of Directors of the Company has considered and approved raise of further equity by way of preferential issue of share warrants up to 5% of the existing equity of the Company exercisable into equal number of equity Shares of Rs.5 each to the promoters/ Promoter Group as per "Guidelines on Preferential Issues" under Chapter XIII of the SEBI (DIP) Guidelines, 2000, subject to the shareholders approval."25 Jan · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 119915 lacs for quarter ending on 31-DEC-2007 against Rs. 147837 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 6255 lacs for the quarter ending on 31-DEC-2007 against Rs. 10563 lacs for the quarter ending on 31-DEC-2006.25 Jan · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 76370 lacs for quarter ending on 31-DEC-2007 against Rs. 115339 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 4229 lacs for the quarter ending on 31-DEC-2007 against Rs. 50349 lacs for the quarter ending on 31-DEC-2006.21 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated January 21, 2008, titled "Dr. Reddy's announces settlement of Exelon(R) (rivastigmine tartrate) ANDA litigation with Novartis". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated January 16, 2008, titled "Dr. Reddy's launches Supanac(R) - (Diclofenac potassium)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Jan · Board meeting
To, interalia consider and take on record the unaudited financial results of the Company for the quarter and nine months ended December 31, 2007.4 Jan · Allotment of Equity Shares
Dr. Reddy's Laboratories Ltd. has informed the Exchange that "Pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002, the Compensation Committee of the Board of Directors of the Company has allotted 3,510 equity shares of Rs.5 each of the Company on January 04, 2008, to Employees who have exercised their Stock Options".
Dec 2007
11 Dec · Management
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that "Mr. Girish Tekchandani, Asst. Company Secretary has resigned and relieved from our Company with effect from December 7, 2007".
Nov 2007
26 Nov · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated November 26, 2007 titled "Sygnis AG and DR.Reddy's Sign Exclusive Supply Collaboration for AX200 in Stroke". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Nov · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated November 26, 2007, titled "Argenta Discovery and Dr Reddy's progress pre-clinical anti-inflammatory candidate to treat chronic respiratory disease". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2007
24 Oct · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated October 24, 2007, titled "Dr. Reddy's Q2 FY08 revenue at Rs 12,670 million; Net Income at Rs 2,672 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements) For more details click here.24 Oct · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 125570 lacs for quarter ending on 30-SEP-2007 against Rs. 194396 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 11060 lacs for the quarter ending on 30-SEP-2007 against Rs. 29250 lacs for the quarter ending on 30-SEP-2006.24 Oct · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 85040 lacs for quarter ending on 30-SEP-2007 against Rs. 83645 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 12500 lacs for the quarter ending on 30-SEP-2007 against Rs. 27266 lacs for the quarter ending on 30-SEP-2006.24 Oct · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 85040 lacs for quarter ending on 30-SEP-2007 against Rs. 83645 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 12500 lacs for the quarter ending on 30-SEP-2007 against Rs. 27266 lacs for the quarter ending on 30-SEP-2006.11 Oct · Board meeting
Meeting on 24 Oct 2007: “Unaudited Results for Qtr & Half year ended Sep 30, 2007”8 Oct · Allotment of Equity Shares
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that : "Pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002, the Compensation Committee of the Board of Directors of the Company has allotted 34,700 equity shares of Rs. 5 each of the Company on October 5, 2007, to Directors/Employees who have exercised their Stock Options."
Sep 2007
28 Sep · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated September 28, 2007, titled "Dr. Reddy's Annual Report on Form 20-F for year ended March 31, 2007 available on the Company's Website". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Sep · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated September 28, 2007, titled "Dr. Reddy's commences operations in Philippines". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Sep · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated September 13, 2007, titled "Dr. Reddy's receives USFDA approval for Ranitidine (Zantac TM) Tablets, 150mg (OTC)". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Sep · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated September 05, 2007, titled "Dr. Reddy's enters the Dermatology topical anti-fungal market with the launch of 'Ebernet TM'-(Eberconazole)". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2007
1 Aug · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated August 01, 2007, titled "Rheoscience and Dr. Reddy's commence the first Phase III trial of Balaglitazone (DRF 2593)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2007
25 Jul · Meeting
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that the members of the Company passed the resolutions unanimously at the Annual General Meeting of the Company held on July 24, 2007. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 23, 2007, titled "Dr. Reddy's Q1 FY08 revenue at Rs 12,018 million; Net income at Rs 1,825 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Jul · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 118809 lacs for quarter ending on 30-JUN-2007 against Rs. 133676 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 18723 lacs for the quarter ending on 30-JUN-2007 against Rs. 12892 lacs for the quarter ending on 30-JUN-2006.23 Jul · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 72770 lacs for quarter ending on 30-JUN-2007 against Rs. 70093 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 14569 lacs for the quarter ending on 30-JUN-2007 against Rs. 13181 lacs for the quarter ending on 30-JUN-2006.10 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 10, 2007, titled "Dr. Reddy's launches Glimy MP1 and Glimy MP2". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Jul · Meeting
Dr. Reddy'S Laboratories Ltd. has submitted to the Exchange a copy of the notice of the Annual General Meeting of the Company to be held on July 24, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Jul · Allotment of Equity Shares
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that: "Pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002, the Compensation Committee of the Company has allotted 47,590 equity shares of Rs.5 each of the Company on July 10, 2007, to Employees who have exercised their Stock Options".10 Jul · Meeting
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that the dividend, which may be declared at the Annual General Meeting scheduled to be held on July 24, 2007, shall be paid to the shareholders on or after July 30, 2007.10 Jul · Board meeting
Meeting on 23 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
Jun 2007
26 Jun · Allotment of Equity Shares
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that: "Pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002, the Compensation Committee of the Company has allotted 137,672 equity shares of Rs.5 each of the Company on June 21, 2007, to Directors/Employees who have exercised their Stock Options".18 Jun · Corporate action
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that: "The register of members and transfer register of the Company would remain closed from July 10 to July 14, 2007 (both days inclusive) for the purpose of payment of Dividend for the year 2006-07".15 Jun · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated June 15, 2007, titled "Dr. Reddy's commences operations in Nigeria". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Jun · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated June 08, 2007, titled "Dr. Reddy's enters the Dermatology topical steroid market with the launch of 'UltravexTM' - (Halobetasol)". A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Jun · Management
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that: "The Board of Directors have appointed Ms.Kalpana Morparia as an Additional Director on the Board of the Company by way of a circular resolution dated June 05, 2007".
May 2007
18 May · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated May 18, 2007 , titled "Dr. Reddy's FY07 revenue at Rs.65,095 million (US$ 1.5 billion) Net Income at Rs. 9,327 million (US$ 216 million"". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 May · Management
Dr. Reddy'S Laboratories Ltd. has informed the Exchange with respect to the Board Meeting held on May 18, 2007 that: "(1) The Board of Directors has appointed Dr. J P Moreau as Additional Director on the Board of the Company. (2) The Compensation Committee has granted 466,460 stock options including 87,500 ADR linked stock options to the employees of the Company. The shares covered by such options are 466,460. The options have been granted at a price of Rs.5 per option. The options may be exercised in a phased manner after a vesting period of 12 months but before completion of five years from the date of vesting".18 May · Dividend
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that the Board of Directors at its meeting held on May 18, 2007 have recommended a final dividend of 75% i.e. Rs. 3.75 per share of face value of Rs.5 on the enhanced share capital due to bonus issue in August 2006.4 May · Board meeting
To interalia, consider and take on record the Audited Financial Results of the Company for the year ended March 31, 2007 and recommend the payment of dividend for the financial year 2006 - 07.
Apr 2007
30 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated April 30, 2007, titled "Dr. Reddy's announces new R&D Chief". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated April 30, 2007, titled "Dr Reddy's launches Reditux(TM)- Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release, dated April 25, 2007, titled "Dr. Reddy's announces the launch of Zolpidem Tartrate tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release, dated April 24, 2007, titled "Dr. Reddy's employees awarded PG certificates from BITS Pilani." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release, dated April 17, 2007, titled "Dr. Reddy's is the first Participant in United States Pharmacopoeia's New Pharmaceutical Ingredient Verification Programme". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Apr · Grant of Options
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that: "The Company has granted 126,418 stock options at par value of Rs.5 per option, to the US Employees of the Company at the meeting of the Compensation Committee of the Board of Directors of the Company held on April 5, 2007. The shares covered by such options are 126,418. The vesting period of these options is in a phased manner over a period of four years. The options may be exercised within a period of five years from the date of vesting".5 Apr · Results
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that: "The Company will announce and publish the audited annual results of the Company for the year ended March 31, 2007 instead of unaudited quarterly results for the quarter ended March 31, 2007".
Mar 2007
21 Mar · Allotment of shares
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that: "Pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002, the Compensation Committee of the Company has allotted 11,836 equity shares of Rs.5 each of the Company on March 20, 2007, to Employees who have exercised their Stock Options".
Feb 2007
16 Feb · Allotment of shares
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that "Pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002, the Compensation Committee of the Company has allotted 70,782 equity shares of Rs.5 each of the Company on February 16, 2007, to a Director and Employees who have exercised their Stock Options".